TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with clinically definite Multiple Sclerosis (MS, all MS subtypes);~2. Age 18 years or older;~3. Presence of chronic, problematic fatigue that, in the opinion of the patient, has interfered with their daily activities for ≥ 3 months;~4. Average Fatigue Severity Scale (FSS) score greater or equal to 4 at screening.~Exclusion Criteria:~1. Current shift work sleep disorder, or narcolepsy diagnosed with polysomnography and multiple sleep latency test~2. History of MS relapse within the last 30 days prior to screening (participants will be considered eligible after the 30-day window);~3. Current stimulant or wake-promoting agent use (such as amantadine, modafinil, methylphenidate, or amphetamine) within 30 days of screening;~4. Pregnancy or breastfeeding;~5. Reliance on hormonal contraception AND concomitant unwillingness to use alternative non-hormonal means of birth control (spermicide or condoms) during the course of the study;~6. Current suicidal ideation (SI) with intent or plan;~7. Known hypersensitivity to modafinil or armodafinil or its inactive ingredients;~8. History of the following cardiovascular conditions: recent myocardial infarction (last 6 months prior to screening), unstable angina, left ventricular hypertrophy, mitral valve prolapse, NYHA class III or IV congestive heart failure;~9. History of prescription or illicit stimulant abuse (such as cocaine, amphetamine, methamphetamine);~10. Any other medical, neurological, or psychiatric condition that, in the opinion of the investigators, could affect participant safety or eligibility.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cognitive Behavioral Therapy (Type: ACTIVE_COMPARATOR): 8 weekly telephone-based sessions and 2 booster sessions
- Modafinil (Type: ACTIVE_COMPARATOR): 50-400 mg per day (oral)
- Cognitive Behavioral Therapy + Modafinil (Type: ACTIVE_COMPARATOR): Telephone-based cognitive behavioral therapy (8 weekly therapy sessions and 2 booster sessions) + Modafinil 50-400 mg per day (oral)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has recurrent MDD as the primary diagnosis according to DSM-IV-TR™ criteria (classification code 296.3x)~* The patient has a MADRS total score \>=26~* The patient has a CGI-S score \>=4~* The patient has had the current episode of MDE for \>3 months~Exclusion Criteria:~* Any current anxiety psychiatric disorder as defined in the DSM-IV TR~* Current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV TR~* Current diagnosis or history of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) as defined in the DSM-IV TR~* Use of any psychoactive medication 2 weeks prior to screening and during the study~* The patient is at significant risk of suicide or has a score \>=5 on Item 10 (suicidal thoughts) of the MADRS, or has attempted suicide within 6 months prior to the Screening Visit~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Vortioxetine: 15 mg (Type: EXPERIMENTAL): None
- Vortioxetine: 20 mg (Type: EXPERIMENTAL): None
- Duloxetine: 60 mg (Type: OTHER): Active Reference

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age over 18 year old~* Cochin Hand Function Scale (CHFS) \> 20/90~Exclusion Criteria:~* new vasodilators or immunosuppressive therapy for SSc in the 3 months prior to enrolment~* new vasodilators or immunosuppressive therapy for SSc during the 6-month follow-up~* clinical or radiological signs of digital infection~* positive status for HIV~* positive status for hepatitis B or C~* positive status for human T-cell leukemia virus 1-2~* positive status for syphilis~* pregnancy~* BMI less than 17kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SVF injection (Type: EXPERIMENTAL): SVF was obtained from lipoaspirates, using an automated processing system, and subsequently injected into the subcutaneous tissue of each finger in contact with neurovascular pedicles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months~* Subjects on premixed human or analogue insulin or self-mixed insulin regimen, containing 20-40 % fast/rapid-acting component, once daily (OD) or twice daily (BID), with or without oral antidiabetic drugs) (OADs) (metformin, sulphonylurea (SU), glinides, alpha-glucosidase inhibitor, DPP-4 (dipeptidyl peptidase-4) inhibitor and pioglitazone), for at least 3 months before Visit 1~* HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis~* Body Mass Index (BMI) below or equal to 40.0 kg/m\^2~Exclusion Criteria:~* Treatment with other insulin regimens than those listed in key inclusion criterion no. 2 within 3 months~* Treatment with rosiglitazone or glucagon-like peptide-1 (GLP-1) receptor agonists (exenatide, liraglutide) within 3 months prior to visit 1~* Cardiovascular disease within the last 6 months prior to visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty~* Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements~* Cancer and medical history of cancer (except basal cell skin cancer and squamous cell skin cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDegAsp BID (Type: EXPERIMENTAL): None
- BIAsp 30 BID (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient with tricuspid regurgitation and right heart failure after left heart valves replacement~2. Patients who takes existing diuretic~3. The patient is willing to participate in the study~Exclusion Criteria:~1. Patients with hypersensitivity to study drug~2. Anuric patients~3. Patients with hypernatremia~4. Female patients who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant~5. Malignant tumor~6. Patients with serious hepatic disorder or Serious Renal failure~7. Patients otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- trial group(tolvaptan group) (Type: ACTIVE_COMPARATOR): trial group (tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv,n=20)
- control group (Type: PLACEBO_COMPARATOR): control group(placebo 15mg/d po(10 days) +torasemide 20mg/d iv,n=20)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Serum and Tissue Cefazolin Concentrations in Patients Undergoing Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or above~2. Body mass index (BMI) of 35 or greater at the time of the first obstetric clinic visit~3. Undergoing cesarean delivery~Exclusion Criteria:~1. BMI less than 35.~2. Not undergoing Cesarean delivery.~3. Age less than 18 years.~4. Pre-existing infection.~5. Allergy to cephalosporin medications or a history of an anaphylactic reaction to penicillin.~6. Cesarean delivery being performed under emergent circumstances.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 gram dose of cefazolin (Type: ACTIVE_COMPARATOR): 2 gram dose of pre-operative cefazolin
- 4 gram Dose (Type: EXPERIMENTAL): 4 gram dose of pre-operative prophylaxis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients in suspicion of breast cancer by mammography or ultrasonography,and being able to provide basic information and sign the written informed consent form~Exclusion Criteria:~* The exclusion criteria included claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study, and undergoing any preceding local or systemic therapies that might interfere with HER2 binding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 99mTc-HPArk2 SPECT/CT (Type: EXPERIMENTAL): The patients were injected with 11.1 (MBq) per kilogram body weight of 99mTc-HPArk2 in one dose intravenously and underwent SPECT/CT scan 30-60 min later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Rheumatoid Arthritis~* At least 3 months prior treatment with Methotrexate (MTX)~* At least 10 swollen joints and 12 tender joints and C-Reactive Protein of at least 1 mg/dl~* Washout required for other disease modifying anti-rheumatic drugs (DMARDS)~Exclusion Criteria:~* participants who have failed more than 3 DMARDs~* participants previously treated with an approved biologic drug~* History of cancer in the last 5 years~* Severe or recurrent bacterial infection~* Any previous or current medical conditions that are contraindications to the use of TNF blocking agents~* Women of Child Bearing Potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]) (Type: ACTIVE_COMPARATOR): Days 1-365
- Infliximab + MTX (DB) (Type: ACTIVE_COMPARATOR): Days 1-365
- Placebo + MTX (DB) (Type: PLACEBO_COMPARATOR): Days 1-197
- Placebo + MTX switched to abatacept + MTX (DB) (Type: EXPERIMENTAL): Participants received placebo plus methotrexate for days 1-197, and abatacept plus methotrexate for days 198-365
- Abatacept (open-label) (Type: EXPERIMENTAL): Days 365 to 729 All participants receive Active Drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Age greater than or equal to 2 years~* Known or suspected somatostatin receptor positive tumor such as carcinoid; neuroendocrine tumor; neuroblastoma; medulloblastoma; pheochromocytoma. Supporting evidence may include MRI, CT, biochemical markers, and or pathology report.~* Karnofsky performance status or Lansky Play Scale status of greater than 50 (or ECOG/WHO equivalent)~* Subject is male; or is a female who is either pre-menarchal, surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (\> 1 years without menses), non-lactating, or of childbearing potential for whom a serum pregnancy test (with the results known prior to investigational product administration) is negative. A negative serum pregnancy test will be required for all female subjects with child bearing potential. If a false pregnancy test is suspected, e.g., perimenopausal condition, an obstetrician will be consulted to determine if she is/is capable of becoming pregnant.~Exclusion Criteria:~* Subject weighs more than 400 pounds (Subjects who weigh more than 400 pounds will not be able to fit inside the imaging machines).~* Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.)~* Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)~* Does the subject have any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance?

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 68Ga-DOTATOC PET/CT (Type: EXPERIMENTAL): 68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Treatment of Colon Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified locally advanced T3 or T4 colon cancer assessed by CT scan~* Analysis of KRAS, BRAF, PIK3CA~* Age ≥18 år~* Performance status ≤ 2~* Hematology~  * ANC ≥ 1.5x10\^9/l. Thrombocytes ≥ 100x10\^9/l.~* Biochemistry~  * Bilirubinaemia ≤ 3 x UNL. ALAT ≤ 5 x UNL~* Consent to translational research~* Fertile women must present a negative pregnancy test and use secure birth control during and 3 months after treatment.~* Written and orally informed consent.~Exclusion Criteria:~* Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment, active severe infections or other concurrent disease.~* Peripheral neuropathy NCI grade \>1~* Other malignant disease within 5 years prior to enrollment, except basal cell squamous carcinoma of the skin and cervical carcinoma-in-situ~* Other investigational treatment within 30 days prior to treatment start~* History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.~* Bleeding tumors~* Hypersensitivity to one or more of the substances

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy only (Type: OTHER): Chemotherapy only, if mutations in KRAS, BRAF or PIK3CA gene
- Chemotherapy + biological treatment (Type: OTHER): Addition of biological treatment, if no mutations in KRAS, BRAF, and PIK3CA genes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Etanercept in Active RA Despite Methotrexate Therapy in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients had to be at least 18 years of age~* fulfilled the 1987 revised classification criteria for RA by in American College of Rheumatology (ACR)~* met the guidelines for the proper use of ETN in Japan (having at least 6 tender joints and 6 swollen joints~* either serum C-reactive protein more than 2 mg/dl or ESR no less than 28 mm at 1 hour, with adequate safety profiles)~* be ACR functional class I-III~* have been receiving MTX 6 mg/week for a minimum of 3 months at a stable dose for at least 4 weeks at the time of study enrollment~Exclusion Criteria:~* Patients who required concurrent use of prednisone (PSL) \>10 mg/day, or its equivalent, were excluded from study entry~* the start of dose increment of PSL equivalents within 3 months of the study enrollment~* experience of antirheumatic therapy except for MTX and PSL equivalents~* previous treatment with ETN or any other biological treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ETN Alone (Type: ACTIVE_COMPARATOR): etanercept (25mg, twice/week, s.c.)
- ETN+MTX (Type: ACTIVE_COMPARATOR): etanercept (25mg, twice/week, s.c.) combined with methotrexate (6-8mg/week)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Intrauterine pregnancy confirmed by ultrasound~2. Estimated gestational age between 12-28 weeks~3. Confirmed to be HIV-infected by Uganda country standard rapid HIV test~4. 16 years of age or older~5. Residency within 30 km of the study clinic~6. Provision of informed consent~7. Agreement to come to the study clinic for any febrile episode or other illness and avoid medications given outside the study protocol~8. Plan to deliver in the hospital~Exclusion Criteria:~1. History of serious adverse event to TS or DP~2. Refusal to take cART during pregnancy or as part of routine HIV care~3. Active medical problem requiring inpatient evaluation at the time of screening~4. Intention of moving more than 30 km from the study clinic~5. Active WHO stage 4 condition not stable under treatment~6. Signs or symptoms of early or active labor~7. Currently on ritonavir~8. Currently taking drugs associated with known risk of Torsades de pointes~9. Currently taking CYP3A inhibitor medications which potentially inhibit the metabolism of piperaquine~10. History of cardiac problems or fainting

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Daily TS + Monthly DP pregnancy (Type: ACTIVE_COMPARATOR): Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
- Daily TS + DP Placebo pregnancy (Type: PLACEBO_COMPARATOR): Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete